MAIA Biotechnology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
MAIA NYSE American 2834 maiabiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MAIA Biotechnology, Inc.

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - Jun 18th, 2026 6:30 am
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - Jun 10th, 2026 7:15 am
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - Jun 4th, 2026 7:45 am
Sector Update: Healthcare Stocks Higher Late Afternoon - Jun 3rd, 2026 1:43 pm
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - Jun 3rd, 2026 7:45 am
MAIA Biotechnology Announces Open Market Purchases by CEO and Director - Jun 2nd, 2026 7:45 am
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology - Jun 1st, 2026 6:00 am
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - May 18th, 2026 6:00 am
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer - Apr 16th, 2026 7:20 am
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - Apr 8th, 2026 7:00 am
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - Mar 31st, 2026 7:15 am
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock - Mar 4th, 2026 2:00 pm
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock - Mar 2nd, 2026 8:45 pm
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Mar 2nd, 2026 3:00 pm
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market - Feb 24th, 2026 6:45 am
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum - Jan 20th, 2026 8:15 am
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings - Dec 24th, 2025 6:01 am
MAIA Biotechnology Announces $1.51 Million Private Placement - Dec 16th, 2025 2:15 pm
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates - Dec 11th, 2025 11:00 am
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer - Dec 11th, 2025 7:00 am